An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors

Current Treatment Options in Oncology

Volumn 16, Issue 11, 2015, Pages

  Neagu, Martha R ^a,b   Reardon, David A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Autologous T cells; CAR T cells; Checkpoint blockade; EGFRvIII; GBM; Immunotherapy; Rindopepimut; Vaccines

Indexed keywords

BEVACIZUMAB; BMS 936559; CANCER VACCINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENDRITIC CELL VACCINE; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLIOVAC; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PEPTIDE COMPLEX VACCINE; INTERLEUKIN 12; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; RINDOPEPIMUT; SIPULEUCEL T; TEMOZOLOMIDE; TICILIMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; TISSUE EXTRACT;

ADOPTIVE TRANSFER; ANTIBODY RESPONSE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; BRAIN TUMOR; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLITIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMOLYSIS; GLIOBLASTOMA; GLIOMA; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOPATHOLOGY; INJECTION SITE REACTION; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHADENOPATHY; MELANOMA; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NEPHRITIS; NEUROBLASTOMA; NEUROPATHY; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PNEUMONIA; PONTINE GLIOMA; RASH; REVIEW; SALVAGE THERAPY; TUMOR ESCAPE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; ADJUVANT RADIOTHERAPY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; IMMUNOTHERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; SURVIVAL RATE; TRENDS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DACARBAZINE; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TISSUE EXTRACTS;

EID: 84944058669     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-015-0371-3     Document Type: Review

References (104)

1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro-Oncology. 2014;16 Suppl 4:iv1–63. doi:10.1093/neuonc/nou223.
2. Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2015;163:1–14. doi:10.1007/978-3-319-12048-5_1.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126.
4. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro-Oncology. 2014. doi:10.1093/neuonc/nou304.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.1056/NEJMoa043330.
6. Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro-Oncology. 2010;12(7):725–35. doi:10.1093/neuonc/noq030.
7. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66. doi:10.1016/S1470-2045(09)70025-7.
8. Chinot OL, Wick W, Cloughesy T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(21):2049.
9. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2009;27(28):4733–40. doi:10.1200/JCO.2008.19.8721.
10. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. doi:10.1056/NEJMoa1308573.
11. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–53. doi:10.1016/S1470-2045(14)70314-6.
12. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18. doi:10.1056/NEJMoa1215134. This study shows the first clinical efficacy of adoptive CAR T cell transfer.
13. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
14. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. doi:10.1056/NEJMoa1001294.
15. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. doi:10.1056/NEJMoa1412082. This study shows durable and robust anti-tumor effects of PD-1 blockade in melanoma.
16. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17. doi:10.1016/S0140-6736(14)60958-2.
17. Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20(22):5620–9. doi:10.1158/1078-0432.CCR-14-0832.
18. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, et al. Immunotherapy advances for glioblastoma. Neuro-Oncology. 2014;16(11):1441–58. doi:10.1093/neuonc/nou212.
19. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol. 1992;148(5):1404–10.
20. Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-Oncology. 2012;14(5):584–95. doi:10.1093/neuonc/nos014.
21. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(23):8304–11. doi:10.1158/1078-0432.CCR-04-2588.
22. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res: Off J Am Assoc Cancer Res. 1999;5(10):2963–70.
23. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(16):5166–72. doi:10.1158/1078-0432.CCR-08-0320.
24. Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol. 1995;146(2):317–22.
25. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology. 2006;8(3):261–79. doi:10.1215/15228517-2006-008.
26. Jacobs JF, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJ, Wesseling P, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol. 2010;225(1-2):195–9. doi:10.1016/j.jneuroim.2010.05.020.
27. Jansen T, Tyler B, Mankowski JL, Recinos VR, Pradilla G, Legnani F, et al. FasL gene knock-down therapy enhances the antiglioma immune response. Neuro-Oncology. 2010;12(5):482–9. doi:10.1093/neuonc/nop052.
28. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. doi:10.1146/annurev.immunol.26.021607.090331.
29. Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005;51(4):279–85. doi:10.1002/glia.20201.
30. Walker DG, Chuah T, Rist MJ, Pender MP. T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. J Neuroimmunol. 2006;175(1–2):59–68. doi:10.1016/j.jneuroim.2006.03.006.
31. Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, et al. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 2015;33(23):2690–6. doi:10.1016/j.vaccine.2015.03.095.
32. Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013;12(6):597–615. doi:10.1586/erv.13.41.
33. Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT. Vaccine therapies for patients with glioblastoma. J Neuro-Oncol. 2014;119(3):531–46. doi:10.1007/s11060-014-1502-6.
34. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519(7543):366–9. doi:10.1038/nature14320. This is elegant study demonstrates that tetanus toxoid can significantly augment anti-glioma immune responses from vaccination.
35. Abecassis IJ, Morton RP, Nerva JD, Kim LJ. Immunotherapy for secondary glioblastoma multiforme: toward an isocitrate dehydrogenase vaccine. World Neurosurg. 2014;82(6):933–5. doi:10.1016/j.wneu.2014.10.006.
36. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014;512(7514):324–7. doi:10.1038/nature13387. A systematic approach to creating an anti-IDH-1 R132H petide vaccine, which may in time allow for targeting lower grade gliomas. This paper also shows that IDH-1R132H may be an inherently immunogenic target in patients.
37. Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, et al. alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer. 2012;12:623. doi:10.1186/1471-2407-12-623.
38. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, et al. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013;36(2):152–7. doi:10.1097/CJI.0b013e3182811ae4.
39. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon 2nd JE, Lally-Goss D, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8(10):2773–9. doi:10.1158/1535-7163.MCT-09-0124.
40. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol, Immunother: CII. 2013;62(1):125–35. doi:10.1007/s00262-012-1319-0. This multi-epitope vaccine has now shown promising results in Phase 2 trials.
41. Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert Rev Vaccines. 2012;11(2):133–44. doi:10.1586/erv.11.177.
42. Neagu MR, Reardon DA. Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? Immunotherapy. 2015. doi:10.2217/imt.15.39.
43. Patel MA, Kim JE, Ruzevick J, Li G, Lim M. The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers. 2014;6(4):1953–85. doi:10.3390/cancers6041953.
44. Swartz AM, Batich KA, Fecci PE, Sampson JH. Peptide vaccines for the treatment of glioblastoma. J Neuro-Oncol. 2014. doi:10.1007/s11060-014-1676-y.
45. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res: Off J Am Assoc Cancer Res. 2003;9(11):4247–54.
46. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(31):4722–9. doi:10.1200/JCO.2010.28.6963.
47. Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, et al. ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology. 2015;33(suppl;abstr 2009) Rindopepimut is the most advanced vaccine in development for glioblastoma. The ReACT study is the first randomized trial to demonstrate a survival benefit for any immunotherapeutic among GBM patients.
48. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 2011;13(3):324–33. doi:10.1093/neuonc/noq157.
49. Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid. 2012;7:93–103. doi:10.2147/CE.S29001.
50. Ampie L, Choy W, Lamano JB, Fakurnejad S, Bloch O, Parsa AT. Heat shock protein vaccines against glioblastoma: from bench to bedside. J Neuro-Oncol. 2015;123(3):441–8. doi:10.1007/s11060-015-1837-7.
51. Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19(1):205–14. doi:10.1158/1078-0432.CCR-11-3358.
52. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-Oncology. 2014;16(2):274–9. doi:10.1093/neuonc/not203. This autologous heat-shock protein vaccine shows intriguing results.
53. Bloch O, Raizer JJ, Lim M, Sughrue M, Komotar R, Abrahams J, O’Rourke D, D’Ambrosio A, Bruce JN, Parsa A. Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015;33(suppl; abstr 2011).
54. Lawler SE. Cytomegalovirus and glioblastoma: controversies and opportunities. J Neuro-Oncol. 2015;123(3):465–71. doi:10.1007/s11060-015-1734-0.
55. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 2008;10(1):10–8. doi:10.1215/15228517-2007-035.
56. Priel E, Wohl A, Teperberg M, Nass D, Cohen ZR. Human cytomegalovirus viral load in tumor and peripheral blood samples of patients with malignant gliomas. J Clin Neurosci: Off J Neurosurg Soc Australasia. 2015;22(2):326–30. doi:10.1016/j.jocn.2014.06.099.
57. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008;108(5):963–71. doi:10.3171/JNS/2008/108/5/0963.
58. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(16):5900–11. doi:10.1158/1078-0432.CCR-05-0559.
59. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005;102(44):16013–8. doi:10.1073/pnas.0500090102.
60. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014;124(3):453–62. doi:10.1182/blood-2014-04-567933.
61. Zhang GL, Ansari HR, Bradley P, Cawley GC, Hertz T, Hu X, et al. Machine learning competition in immunology—prediction of HLA class I binding peptides. J Immunol Methods. 2011;374(1–2):1–4. doi:10.1016/j.jim.2011.09.010.
62. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):1081–91. doi:10.1158/0008-5472.CAN-11-3722.
63. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(7):2039–47. doi:10.1158/1078-0432.CCR-11-1823.
64. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. doi:10.1056/NEJMoa1200694.
65. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMoa1200690.
66. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. doi:10.1056/NEJMoa1104621.
67. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(21):2691–7. doi:10.1200/JCO.2012.41.6750.
68. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65. doi:10.1016/S1470-2045(12)70090-6.
69. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res: Off J Am Assoc Cancer Res. 2007;13(7):2158–67. doi:10.1158/1078-0432.CCR-06-2070.
70. Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med. 2013;210(13):2803–11. doi:10.1084/jem.20130678.
71. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343–9. doi:10.1016/j.ijrobp.2012.12.025.
72. Reardon D, Gokhale P, Ligon K, Liao X, Rodig S, Zhou J, et al. Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinagtorial therapy. Neuro-Oncology. 2014;16:v110–8. doi:10.1093/neuonc/nou258.
73. Suryadevara CM, Verla T, Sanchez-Perez L, Reap EA, Choi BD, Fecci PE, et al. Immunotherapy for malignant glioma. Surg Neurol Int. 2015;6 Suppl 1:S68–77. doi:10.4103/2152-7806.151341.
74. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889–97. doi:10.1056/NEJM198704093161501.
75. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(13):4550–7. doi:10.1158/1078-0432.CCR-11-0116.
76. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23(10):2346–57. doi:10.1200/JCO.2005.00.240.
77. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35. doi:10.1182/blood-2009-08-239186.
78. Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74(13):3466–76. doi:10.1158/0008-5472.CAN-14-0296. This approach uses autologous T cell transfer to target CMV epitopes expressed by glioma cells.
79. Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, et al. Myeloablative temozolomide enhances CD8(+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3), e59082. doi:10.1371/journal.pone.0059082.
80. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709–20. doi:10.1182/blood-2011-10-384388.
81. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264–70. doi:10.1038/nm.1882.
82. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther: J Am Soc Gene Ther. 2013;21(3):629–37. doi:10.1038/mt.2012.210.
83. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther: J Am Soc Gene Ther. 2013;21(11):2087–101. doi:10.1038/mt.2013.185.
84. Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PLoS One. 2014;9(4), e94281. doi:10.1371/journal.pone.0094281.
85. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012;23(10):1043–53. doi:10.1089/hum.2012.041.
86. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2015. doi:10.1158/1078-0432.CCR-15-0428.
87. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(11):1963–72. doi:10.1200/JCO.2009.26.3541.
88. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(23):7412–20. doi:10.1158/1078-0432.CCR-09-1624.
89. Okada H, Weller, M., Huang, R. et. al. Immunotherapy Response Assessment in Neuro-Oncology (iRANO): a report of the RANO Working Group Lancet Oncology. 2015;In Press.The iRANO Working Group redefines response criteria for immunotherapy among neuro-oncology patients in this manuscript.
90. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. doi:10.1056/NEJMoa1302369. This work shows enhanced efficacy of combination CTLA-4 and PD-1 blockade in treatment of melanoma.
91. Weathers SP, Gilbert MR. Current challenges in designing GBM trials for immunotherapy. J Neuro-Oncol. 2015;123(3):331–7. doi:10.1007/s11060-015-1716-2.
92. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry Jr WT. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012;35(5):385–9. doi:10.1097/CJI.0b013e3182562d59.
93. Duraiswamy J, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors—response. Cancer Res. 2014;74(2):633–4. doi:10.1158/0008-5472.CAN-13-2752. discussion 5.
94. Chow KK, Hara W, Lim M, Li G. Combining immunotherapy with radiation for the treatment of glioblastoma. J Neuro-Oncol. 2015;123(3):459–64. doi:10.1007/s11060-015-1762-9.
95. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31. doi:10.1056/NEJMoa1112824.
96. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95. doi:10.1182/blood-2009-02-206870.
97. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180(5):3132–9.
98. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71. doi:10.1084/jem.20052494.
99. Sims JS, Ung TH, Neira JA, Canoll P, Bruce JN. Biomarkers for glioma immunotherapy: the next generation. J Neuro-Oncol. 2015;123(3):359–72. doi:10.1007/s11060-015-1746-9.
100. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, et al. Immune monitoring using the predictive power of immune profiles. J Immunother Cancer. 2013;1:7. doi:10.1186/2051-1426-1-7.
101. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, et al. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter system. Mol Oncol. 2014;8(3):669–78. doi:10.1016/j.molonc.2014.01.010.
102. Nielsen T, Wallden B, Schaper C, Ferree S, Liu S, Gao D, et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 2014;14:177. doi:10.1186/1471-2407-14-177.
103. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. doi:10.1038/nature13954.
104. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. doi:10.1016/j.ccr.2009.12.020.